By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Company, Ltd. 

4-6-10 Koishikawa, Bunkyo-ku

Tokyo    112-8088  Japan
Phone: 81-3-3817-3700 Fax: n/a


Key Statistics

Ownership: Public

Web Site: Eisai Company
Employees: 7,043
Symbol: ESALY.PK

Company News
Eisai Company (ESALY.PK) Buys Cancer Drug Rights From HUYA Bioscience in $280 Million+ Deal 2/1/2016 5:56:38 AM
Eisai Company (ESALY.PK) Pays $78 Million To Acquire Small China Generic Drugmaker 12/2/2015 12:56:12 PM
Eisai Company (ESALY.PK) To Present Latest Clinical Data On Lenvima (Lenvatinib) And Halaven (Eribulin) At European Cancer Congress 9/14/2015 12:09:11 PM
Eisai Company (ESALY.PK) And Purdue Pharma L.P. Enter Worldwide Collaboration To Develop And Commercialize Lemborexant 8/31/2015 6:11:24 AM
Eisai Company (ESALY.PK) Release: FYCOMPA (perampanel) CIII Demonstrates A Significant Reduction In Primary Generalized Tonic-Clonic (PGTC) Seizure Frequency In Phase 3 Trial Of Patients With Epilepsy Age 12 And Older 8/24/2015 7:36:03 AM
Eisai Company (ESALY.PK) Employees Will Be Offered Biogen (BIIB) Jobs When RTP Campus Ownership Deal Closes 7/16/2015 7:30:31 AM
ASCO15: Eisai Company (ESALY.PK)'s Eribulin Extends Survival in Patients With Rare Cancers 6/1/2015 6:21:20 AM
Eisai Company (ESALY.PK) And Arena Pharmaceuticals, Inc. (ARNA) Complete Registrational Trials Of An Extended Release Formulation Of Lorcaserin 4/10/2015 10:49:00 AM
Battling U.S. Market Headwinds, Eisai Company (ESALY.PK) Cuts 200+ Jobs 4/10/2015 6:00:24 AM
Epizyme (EPZM) Reacquires Rights to Cancer Drug From Eisai Company (ESALY.PK) in Deal Worth $110 Million 3/12/2015 6:22:50 AM